Lack/NN
of/IN
T-cell-mediated/JJ
recognition/NN
of/IN
the/DT
fusion/NN
region/NN
of/IN
the/DT
pml/RAR-alpha/NN
hybrid/NN
protein/NN
by/IN
lymphocytes/NNS
of/IN
acute/JJ
promyelocytic/JJ
leukemia/NN
patients/NNS
./.

In/IN
previous/JJ
studies/NNS
,/,
it/PRP
was/VBD
shown/VBN
that/IN
the/DT
fusion/NN
region/NN
of/IN
the/DT
pml/RAR-alpha/NN
protein/NN
,/,
expressed/VBN
by/IN
acute/JJ
promyelocytic/JJ
leukemia/NN
(/(
APL/NN
)/)
cells/NNS
,/,
can/MD
be/VB
specifically/RB
recognized/VBN
in/FW
vitro/FW
by/IN
donor/NN
(/(
D./NNP
E./NNP
)/)
CD4/NN
T/NN
cells/NNS
in/IN
a/DT
HLA/NN
class/NN
II/CD
DR11-restricted/JJ
fashion/NN
./.
=====
We/PRP
present/VBP
here/RB
the/DT
results/NNS
on/IN
the/DT
recognition/NN
of/IN
several/JJ
pml/RAR-alpha/NN
peptides/NNS
by/IN
APL/NN
patients/NNS
expressing/VBG
HLA/NN
DR11/NN
./.
=====
The/DT
in/FW
vitro/FW
immunization/NN
of/IN
peripheral/JJ
blood/NN
lymphocytes/NNS
from/IN
four/CD
patients/NNS
in/IN
remission/NN
(/(
S.R./NNP
,/,
F.R./NNP
,/,
M.M./NNP
,/,
P./NNP
G./NNP
)/)
with/IN
BCR1/25/NN
,/,
a/DT
25-mer/NN
pml/RAR-alpha/NN
,/,
did/VBD
not/RB
elicit/VB
either/CC
a/DT
polyclonal/JJ
or/CC
a/DT
clonal/JJ
immune/JJ
response/NN
specific/JJ
to/TO
the/DT
peptide/NN
./.
=====
We/PRP
then/RB
generated/VBD
new/JJ
donor/NN
anti-pml/RAR-alpha/JJ
CD4(+)/JJ
T-cell/NN
clones/NNS
./.
=====
These/DT
clones/NNS
were/VBD
tested/VBN
for/IN
their/PRP$
recognition/NN
of/IN
BCR1/25/NN
./.
=====
One/CD
clone/NN
(/(
C3/5/NN
,/,
CD3(+)/JJ
,/,
CD4(+)/JJ
,/,
CD8(-)/JJ
)/)
was/VBD
selected/VBN
for/IN
further/JJ
analysis/NN
./.
=====
Clone/NN
C3/5/NN
showed/VBD
specific/JJ
proliferation/NN
,/,
cytotoxicity/NN
,/,
and/CC
cytokine/NN
(/(
tumor/NN
necrosis/NN
factor/NN
alpha/NN
,/,
granulocyte-macrophage/JJ
colony-stimulating/JJ
factor/NN
)/)
production/NN
when/WRB
challenged/VBN
with/IN
autologous/JJ
lymphoblastic/JJ
cell/NN
lines/NNS
pulsed/VBN
with/IN
peptide/NN
BCR1/25/NN
./.
=====
C3/5/NN
cells/NNS
developed/VBD
specific/JJ
proliferation/NN
and/CC
cytotoxicity/NN
when/WRB
challenged/VBN
with/IN
peptide-pulsed/JJ
lymphoblastic/JJ
cell/NN
lines/NNS
and/CC
peripheral/JJ
blood/NN
lymphocytes/NNS
from/IN
the/DT
four/CD
DR11(+)/JJ
APL/NN
patients/NNS
./.
=====
APL/NN
blasts/NNS
,/,
available/JJ
only/RB
from/IN
patients/NNS
F.R./NNP
and/CC
P.G./NNP
,/,
were/VBD
not/RB
lysed/VBN
by/IN
C3/5/NN
and/CC
were/VBD
unable/JJ
to/TO
present/VB
peptide/NN
BCR1/25/NN
./.
=====
Incubation/NN
of/IN
APL/NN
cells/NNS
with/IN
IFN-gamma/NN
failed/VBD
to/TO
induce/VB
HLA/NN
class/NN
II/CD
molecules/NNS
and/CC
recognition/NN
by/IN
the/DT
C3/5/NN
clone/NN
./.
=====
Since/IN
APL/NN
cells/NNS
do/VBP
not/RB
express/VB
HLA/NN
class/NN
II/CD
molecules/NNS
,/,
we/PRP
tested/VBD
in/IN
two/CD
donors/NNS
(/(
D.E./NNP
and/CC
C.H.R./NNP
)/)
and/CC
in/IN
patients/NNS
S.R./NN
and/CC
P.G./NN
whether/CC
the/DT
use/NN
of/IN
9-mer/NN
peptides/NNS
(/(
BCR1/9/NN
)/)
would/MD
generate/VB
a/DT
CD8/HLA/NN
class/NN
I-restricted/JJ
response/NN
./.
=====
No/DT
peptide-specific/JJ
T-cell/NN
line/NN
or/CC
clone/NN
could/MD
be/VB
generated/VBN
from/IN
both/CC
donors/NNS
and/CC
patients/NNS
./.
=====
These/DT
findings/NNS
are/VBP
discussed/VBN
in/IN
relation/NN
to/TO
possible/JJ
therapeutic/JJ
approaches/NNS
to/TO
the/DT
immunotherapy/NN
of/IN
APL/NN
./.